Presented by expert speakers from leading pharmaceutical companies, these workshops will give you advanced insights into topic areas that the event will address

Can’t make the date? Still register to receive the recording afterwards.

Peptides Webinars

Proteins & Antibodies Digital Workshops


Evaluation Of Host Immune Response To Multi-Specific Antibodies And Other Complex Biotherapeutics

Wednesday 20th May 2020 | 14:00 - 14:25 BST

BORIS GOROVITS, Senior Director, Pfizer

Presentation will focus on the current understanding of the assessment of host immunogenicity response to multi-domain biotherapeutics, including bi-specific antibodies, protein fusion molecules and other complex therapeutics. Related immunogenicity risk factors, required immunogenicity response characterization and related methodologies will be discussed. Current position of regulatory agencies will be reviewed.

Discussing The Opportunities Of Combinations Between Small Molecule And Biologics/Immune Checkpoint Blockade

Wednesday 20th May 2020 | 14:25 - 14:50 BST

CHARLES SINCLAIR, Senior Research Investigator, Bristol-Myers Squibb

IgMs As A Platform For Therapeutic Agonism

Wednesday 20th May 2020 | 14:50 - 15:15 BST

NICHOLAS AGARD, Scientist, Genentech

  • IgMs have 10 or 12 binding subunits and a unique ‘mushroom’ shape that defines the arrangement of cell-surface bound ligands
  • We show this multivalent engagement agonizes clinical targets not addressable by simple IgGs
  • Further engineering and characterization of IgMs helps define their suitability across multiple therapeutic spaces

Challenges in Down-Stream Processing And Analytics Of A Large Diversity Of Molecules/Formats in The Discovery Setting

Wednesday 20th May 2020 | 15:15 - 15:40 BST

JOHN HARLAN, Senior Principal Research Scientist, AbbVie

Downstream processing in support of Biologics Drug Discovery provides challenges that are distinct from those encountered in Development. Here we will discuss the approach we have taken to develop platform processes that can address the large diversity of molecules we encounter in the Discovery setting in the shortened time-lines needed to facilitate the Discovery process, including the “fit for purpose” analytical approach we take, and automated processes we have developed.


The Influence Of Engineering On Aberrant Bispecific Antibody Pharmacokinetics And Disposition

Wednesday 28th May 2020 | 16:00 - 16:25 BST

AMITA DATTA-MANNAN, Research Advisor and Group Leader, Eli Lilly

Bispecifics: A Focus On Anti IL-13/17

Wednesday 28th May 2020 | 16:25 - 16:50 BST

RYAN OWEN, Senior Scientist in Clinical Pharmacology, Genentech

  • Potential utility of bispecifics
  • Theory of anti-IL13/17 – potential for activity on both eosinophilic and neutrophilic inflammation
  • Phase 1 clinical data – PK, Safety, and Immunogenicity data

Targeting Asialoglycoprotein Receptor With Catch-And-Release Antibody

Wednesday 28th May 2020 | 16:50 - 17:15 BST


Asialoglycoprotein receptor (ASGPR) comprising of two subunits is highly expressed on the hepatocytes. ASGPR internalizes into the endosomal compartments and recycles back to the cell surface. We have generated high affinity anti-ASGR1 antibodies and were screened for pH/calcium dependent binding to the receptor. PK/PD data for these novel antibodies and along with simulations of FcRn impact on PK of these antibodies will be presented.

Development Of A Novel Antibody Drug Conjugate Using A Pyrrolobenzodiazepine Derived Drug

Wednesday 28th May 2020 | 17:15 - 17:40 BST

JEFFREY ZHANG, Technical Development Scientist, Genentech

  • Description of the development of an antibody drug conjugate using the THIOMAB platform for increased tolerance and PK
  • Use of a cell killing assay to examine the relationship between potency and free drug


The Impact Of Proline isomerization On Antigen Binding And The Analytical Profile Of A Trispecific Anti-HIV Antibody

Tuesday 9th June 2020 | 16:00 - 16:25 BST

ALESSANDRO MASIERO, Research Scientist, Sanofi

  • Aberrant size exclusion chromatography (SEC) profile and pH dependance
  • Structural and molecular dynamics analyses
  • Correlation of in silico/in vitro data and validation

Antibody Screening Cascades: A Case Study For Biotherapeutic Discovery

Tuesday 9th June 2020 | 16:25 - 16:50 BST

KELLY LOYET, Senior Scientist, Genentech

  • Following target identification for therapeutic development, it is important to assemble a relevant suite of functional assays amenable to screening from hundreds to thousands of antibodies and subsequent confirmation of hits
  • These assays balance high-throughput nature for rapid screening and recapitulation of physiological aspects for best translatability of the lead
  • Here I will present a biotherapeutic antibody discovery case study and future perspectives for developing the best functional assays to fit the project needs

Use Of iBeacon For Formulation Screening

Tuesday 9th June 2020 | 16:50 - 17:15 BST

RAMESH IYER, Principal Research Scientist, AbbVie

Analytical Analysis Of Bispecific Antibodies From The Protein Folding Point Of View

Tuesday 9th June 2020 | 17:15 - 17:40 BST

MARK CHIU, Head of Process Analytical Support for Analytical Resource Team, Janssen

Beyond Binding Kinetics: Stoichiometry Via SPR Can Identify Novel Binding Modes, Assess Ligand Quality And Inform Functional Design In Biopharmaceutical Discovery

Tuesday 9th June 2020 | 17:40 - 18:10 BST

ENRICO DIGIAMMARINO, Principal Research Scientist, AbbVie

We have implemented an often underutilized SPR measure to characterize the function and quality of biological therapeutics: binding stoichiometry. Examples will be discussed showing how it can be used to demonstrate function of biotherapeutic candidates as well as reveal novel binding modes, identify signs of molecular liabilities and aid in engineering functional biotherapeutic molecules.

Peptides Digital Workshops


Investigation On The Fate Of Non-Peptide Related Impurities In Peptide API Manufacturing

Thursday 14th May 2020 | 14:00 - 14:25 BST

Presented by YI YANG, Senior Research Scientist, Ferring Pharmaceuticals

Peptide APIs are generally subjected to stereotypical analyses like RP-HPLC to stochastically detect and quantify the “visible” non-peptide related impurities. Nonetheless, not all non-peptide related impurities could be detected by a uniform analytical method such as RP-HPLC. Moreover, the applied analytical method might not have been sufficiently validated for the purpose of quantification of non-peptide related impurities wrt. specificity, linearity, accuracy, LOD, LOQ, etc. This concern is particularly relevant considering the potentially high toxicity of many non-peptide related impurities.

In the subject talk, a methodology pursued in Ferring Pharmaceuticals will be introduced through predicting the formation of non-peptide related impurities within the scope the peptide API manufacturing process. On top of such prediction, transformation of the assigned non-peptide related impurities through the whole manufacturing process will be subjected to dedicated investigations. Depending on the stage of impurity formation and the toxicity assessment, treatment will be rationally deployed and dedicated analytical methods will be developed to quantify the selected non-related impurities in the final API. Such strategy of non-peptide related impurity treatment in Ferring Pharmaceuticals will be delineated in the talk.

Intracellular Library Screening And Selection To Derive Selective PPI Antagonists

Thursday 14th May 2020 | 14:25 - 14:50 BST

JODY MASON, Professor, University of Bath

  • Protein-protein interactions are compelling drug targets that are often intractable to small molecule
  • Peptides occupy an attractive middle ground between small molecules and much larger biologics in targeting such PPIs
  • We utilise in cell peptide library screening approaches to identify selective peptide-based inhibitors that are capable of functioning within complex cellular environments


Accelerated Forced Degradation Of Therapeutic Peptides In Levitated Microdroplets

Friday 12th June 2020 | 14:00 - 14:25 BST

YONG LIU, Senior Principal Scientist, Merck

  • A new method was developed to study, over the course of seconds, peptide degradation in levitated aqueous microdroplets on a metal dice using the Leidenfrost effect
  • This two-minute reaction and analysis by mass spectrometry workflow was demonstrated through the study of major peptide degradation pathways include deamidation, disulfide bond cleavage, ether cleavage, hydrolysis, and oxidation
  • This work can be applied to rapidly determine the intrinsic stability of therapeutic peptides and to aid formulation development

New Modality Peptides For Advanced Drug Delivery

Friday 12th June 2020 | 14:25 - 14:50 BST

Presented by MARIANNA YANEZ ARTETA, Senior Scientist Formulation/Physical Chemistry, AstraZeneca

Bispecifics Digital Workshops


Using CrossMab Technology For Development Of Bispecific Antibodies

Thursday 2nd July 2020 | 14:00 - 14:25 BST

CHRISTIAN KLEIN, Department Head Cancer Immunotherapy Discovery 3, Roche Innovation Center Zurich

  • Basis of CrossMab technology
  • Engineering features of CrossMabs and application of CrossMab technology for generation of diverse set of bispecific antibody formats
  • CrossMabs in development incuding antiangiogenesis, checkpoint inhibition, T cell bispecific antibodies and antibody fusion proteins
  • Examples of CrossMabs in academic research

Bispecific ADCs Targeting HER2: Intracellular Traffi cking Of The Antibody Dictates The Choice Of Linker-Payload

Thursday 2nd July 2020 | 14:25 - 14:50 BST

JULIAN ANDREEV, Research Fellow, Regeneron

Bispecific ADCs bridging HER2 and high turnover proteins travel to lysosomes and improve effi cacy of HER2 ADCs with non-cleavable linker-DM1. Biparatopic HER2 ADCs induce target internalization and require cleavable linker for greater efficacy. Combining various bispecific antibody approaches with correct linker-payload technology may allow to generate ADCs with better efficacy and safety profiles.

Fusions And DutaFabs: An Update On Roche’s Bispecific Platforms

Thursday 2nd July 2020 | 14:50 - 15:15 BST

MARLON HINNER, Principal Scientist & Group Leader, Roche Innovation Centre Munich

Targeting Bispecifics

Thursday 2nd July 2020 | 15:15 - 15:40 BST

DANIELLE MANDIKIAN, Scientist, Genentech

Looking for more?

All of our past webinars are available for download from our Content HUB, as well as Market Industry Reports, Q&A Sessions, Newsletters and much more.